touchCARDIO
Online/Digital
At touchCARDIO, we push the boundaries of online medical education to bring you innovative formats and valuable insights into learning behaviours. Our educational content enhances your ability to provide better patient care and drive positive change in clinical practice. With patients at the heart of everything we do, we aim to help you significantly improve health outcomes.
Our educational activities, often accredited by ACCME, EBAC, ANCC (for nurses), and ACPE (for pharmacists), are designed to meet your professional needs. Visit our CME page to access this accredited content. Additionally, you can explore our peer-reviewed, open access journal, stay updated with key news from major congresses, and utilize our library of unaccredited educational content. Source
Actions
Media Outlet details
| Scope | International |
|---|---|
| Language | English |
| Country | United Kingdom |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesNew ESC heart failure guidelines simplify classification and introduce ‘foundational’ therapy
New 2026 ESC Guidelines for the management of heart failure introduce major changes to the classification of heart failure and its treatment. The European Society of Cardiology (ESC) has published new guidelines for the management of heart failure (HF), presented today at ESC Congress 2026 in Munich.
Multi-site infective endocarditis complicated by a left ventricular abscess and pseudoaneurysm: A case report
Overview Background Native valve infective endocarditis (IE) is a relatively rare condition with an incidence of 3–7 cases per 100,000 person-years. Even rarer is the occurrence of left ventricular pseudoaneurysm (LVP) as a complication of IE. Case summary A 52-year-old man with insulin-dependent diabetes and well-controlled human immunodeficiency virus was diagnosed with IE with mitral valve vegetations and a left ventricular myocardial abscess, causing an LVP.
Heart Failure | touchCARDIO
Much progress has been made in the management of heart failure in patients with reduced ejection fraction (HFrEF) and the development of therapies for HF with preserved ejection fraction is ongoing. Promising new therapeutics in HF include a dual-acting angiotensin receptor-neprilysin inhibitor, soluble guanylate cyclase (sGC) stimulator and a cardiac myosin activator. It is hoped that gene therapy will be available for patients with HFrEF in the near future.
Congenital Conditions
Congenital heart defects are the most common type of birth defect. Treatment and management depends on the type and severity of the condition and can include medicines, catheter procedures, surgery and heart transplants. Browse the content below where leading experts discuss the latest data in video interviews and short articles from our conference hub, and browse the selection of peer-reviewed articles from our journal portfolio.
Arrhythmia | touchCARDIO
Advances in the understanding of arrhythmias has improved diagnosis and led to the discovery of new therapies. Large-scale studies into the direct oral anticoagulation treatment paradigm continue to improve patient selection, and technological advances such as hand-held ECG devices and implantable loop recorders have been shown to aid in arrhythmia detection.
Atrial Fibrillation
Atrial fibrillation (AF) remains a major clinical challenge in Europe, with ongoing needs for greater precision, safety, and long-term durability in ablation. The recent CE Mark approval of the TactiFlex™ Duo Ablation Catheter, combining high-resolution mapping with emerging pulsed-field ablation (PFA) technology, offers a new option to help address these gaps.
Imaging | touchCARDIO
Coverage from: ACC Highlights Evolocumab is a proprotein convertase subtilisin kexin type 9 inhibitor (PCSK9 inhibitor). When used in combination with statins, reduced plaque volume has been observed in patients with acute coronary syndrome (ACS). In this touchCARDIO interview, we speak with Dr Annapoorna Kini (...
Cardiovascular Disease
Cardiovascular diseases (CVDs) are the number one cause of death globally, taking an estimated 17.9 million lives each year. CVDs describe a number of conditions affecting the heart and circulation, including coronary heart disease, angina, congenital heart disease, hypertension and stroke. The huge and ever-increasing burden of CVDs on individuals and healthcare systems shows the urgent ongoing need for treatments and preventive measures.
Could senolytics change the treatment landscape of age-related diseases? – touchCARDIO
Georgina: My first degree was in sports science, where I specialised in physiology. I then completed a PhD in skeletal muscle and cardiac regeneration, focusing on how the heart and skeletal muscle repair and regenerate themselves. That led me to research stem cells, exercise training, and the administration of growth factors to encourage muscle regeneration. At one point, we were testing stem cell therapy in the heart, but the effects were modest.
Sarcopenic Obesity as a Risk Factor for Cardiovascular Disease: An Underrecognized Clinical Entity – touchCARDIO
Cardiovascular Disease Read Time: 13 mins Copy Link Published Online: Dec 5th 2023 Heart International. 2023;17(2):6-11 DOI: https://doi.org/10.17925/HI.2023.17.2.6 Authors: Aditya John Binu, Nitin Kapoor, Saptarshi Bhattacharya, Kamal Kishor, Sanjay Kalra Quick Links: Overview Sarcopenic obesity (SO) is a chronic condition and an emerging health challenge, in view of the growing elderly population and the obesity epidemic.